DLB Dolby Laboratories Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : DLB Dolby Laboratories

DLB 75.59

-1.4%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cooters who wrote (239)	11/16/2020 11:26:24 AM
From: Cooters	of 311

CFRA MAINTAINS HOLD OPINION ON SHARES OF DOLBY LABORATORIES, INC. 12:36 pm ET November 13, 2020 We lift our 12-month target to $84 from $72 on 25.0x our FY 21 (Sep.) EPS estimate and near the middle of DLB's three-year trading band. We keep our FY 21 EPS estimate of $3.36 and set FY 22's EPS at $3.58. DLB prints adjusted Sep-Q EPS of $0.45 vs. $0.66 the year prior, and exceeded consensus by $0.11. Quarterly revenues were down 9% to $271M, but topped consensus by $26M - the beat was largely attributed to a larger-than-expected true-up ($25M vs. $15M) related to shipments in Broadcast (TVs and set-top boxes) and PCs. Gross margin came in below expectations (85.1% vs. 86.5%) on charges related to obsolete inventory in conferencing hardware. DLB's revenue outlook for Dec-Q (Q1 FY 21) was above expectations ($330M-$360M vs. $278M) as large recoveries related to its largest mobile customer are pulled forward from Mar-Q (Q2 FY 21). DLB's expanded role in flagship handsets and new products in communications (Dolby.io) remain encouraging, but largely reflected in the current valuation multiple, in our view.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next